These results provide further evidence for the importance of the IL-1β pathway for pro-tumor inflammation in lung cancer and suggest canakinumab’s effect may be mediated by delaying inflammation-driven disease progression of diverse molecular subtypes of lung cancer. Here, IL1B is linked to lung cancer.